Spray as you go
PreclinicalSmall molecule
Spray as you go is one of 21 small molecule programs targeting Dexmedetomidine. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Dexmedetomidine
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Spravato
WWim Janssens
Approved
Normodyne
AAlvogen Korea
Approved
Dexmedetomidine Hydrochloride
PfizerPhase 3
Paracetamol
GSKPhase 3
Hyperbaric Bupivacaine
TTanta University
Phase 3
Intranasal Dexmedetomidine
BBaudax Bio
Phase 3
Intranasal Ketamine
JJavelin Pharmaceuticals
Phase 3
Combined Dexmedetomidine-Esketamine
PPeking University First Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dexmedetomidine1 trial
Local1 trial
Transcricoid Injection vs. Spray as You go Method for Local Anaesthesia During EBUS-TBNA
Completed·—·N/A·NCT02981264·365 enrolled
Bronchoscopy1 trial
Transcricoid Injection vs. Spray as You go Method for Local Anaesthesia During Bronchoscopy
Completed·—·N/A·NCT02981277·500 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Spray as you go. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTanta University